Chapter from the book *Advances in the Preclinical Study of Ischemic Stroke*
Downloaded from: http://www.intechopen.com/books/advances-in-the-preclinical-study-of-ischemic-stroke

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Folate Deficiency Enhances Delayed Neuronal Death in the Hippocampus After Transient Cerebral Ischemia

Jun Hyun Yoo
Department of Family Medicine, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

1. Introduction

Transient cerebral ischemia, in which the brain is temporarily deprived of nutrients and oxygen, results in delayed degeneration of vulnerable neurons within the CA1 region of the hippocampus. The pathophysiology of cerebral ischemic disease is a complex series of cellular biochemical process that involves intracellular ATP depletion, excitotoxicity, oxidative stress, microvascular injury, hypercoagulable hemostatic activation, post-ischemic inflammation and final cell death of neuronal, glial, and endothelial cells (Brouns et al, 2009; Jin et al, 2010).

Folate is an essential micronutrient as a methyl donor for the DNA nucleotides synthesis and cytosine methylation for the control of gene expression. Clinically, folate deficiency is linked to megaloblastic anemia and atherothrombotic vascular disease. On the biochemical basis, folate deficiency increases nuclear DNA damage via uracil misincorporation and which induces chromosome breaks (Blount et al, 1997; Fenech, 2010). A metabolic consequence of folate deficiency is the accumulation of intermediate metabolite, homocysteine. Dietary folate deficiency has been shown to decrease mitochondrial folate concentration and mitochondrial DNA content and increase mitochondrial DNA deletion in brain, leading to leakage of ROS and increase of oxidative stress (Chang et al, 2007; Ho et al, 2003; Crott et al, 2005). Electron microscopic finding showed mitochondrial degeneration in the endothelium and perivascular fibrosis in microvascular wall in the rat brain (Kim et al, 2002).

Homocysteine is a toxic amino acid to neuronal and vascular endothelial cells. Numerous epidemiological studies have recognized the association of folate deficiency and hyperhomocysteinemia with increased risk of vascular disease and ischemic stroke (Yoo et al, 1998, 2000, Kang et al, 1992). Hyperhomocysteinemia produces complex alterations in the blood vessels including oxidative stress, endothelial dysfunction and inflammatory response via the activation of transcription factor such as nuclear factor-kB (NF-kB) or activator protein-1(AP-1). Homocysteine upregulate E-selectin, P-selectin, ICAM-1, V-CAM-1, MCP-1 via activation of NF-kB, and AP-1 (Hwang et al, 2008; Woo et al, 2008).

No study has yet evaluated the morphological characteristics of the folate-deficient hippocampus after transient forebrain ischemia. This study examined the delayed neuronal
death and morphologic changes in the hippocampal CA1 region after transient forebrain ischemia in a gerbil model.

2. Materials and methods

2.1 Experimental animals, diets, measurements of body weight and serum homocysteine level

For a detailed description of the present experimental method is referred to the published article (Hwang IK et al, 2008). The animals were fed with the respective diet ad libitum for 3 months. After 3 months on the folate deficient-diets (FAD), blood was taken for analysis of homocysteine levels. Homocysteine levels in serum samples were quantified with the use of an high performance liquid chromatography (Yoo et al, 1998).

2.2 Induction of transient forebrain ischemia and tissue processing for histology

After 3 months of folate deficient-diet, animals were anesthetized with isoflurane in 33% oxygen and 67% nitrous oxide. Bilateral common carotid arteries were isolated and occluded using non-traumatic aneurysm clips. After 5 min of occlusion, the aneurysm clips were removed from the common carotid arteries. The body temperature under free-regulating or normothermic (37 ± 0.5°C) conditions was monitored with a rectal temperature probe and maintained during and after the surgery until the complete recovery from anesthesia. Thereafter, animals were kept on the thermal incubator to maintain the body temperature of animals until the euthanasia. Sham-operated animals served as controls: these sham-operated animals were subjected to the same surgical procedures except no occlusion of common carotid artery.

For the tissue preparation, sham- and ischemia-operated animals were anesthetized and perfused transcardially with 0.1 M phosphate-buffered saline (pH 7.4) followed by 4% paraformaldehyde in 0.1 M phosphate-buffer (pH 7.4). The brains were removed and post-fixed in the same fixative for 6 hours. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight.

2.3 Examination of neuronal damage: Cresyl violet staining

The sections in the hippocampal CA1 region were mounted on gelatin-coated microscopy slides. Cresyl violet acetate (Sigma) was dissolved at 1.0% (w/v) in distilled water, and glacial acetic acid was added to this solution. The sections were stained and dehydrated by immersing in serial ethanol baths, and they were then mounted with Canada balsam (Kanto Chemical, Tokyo, Japan). All animals (n=7 at each time) were sampled according to the time lines to evaluate the evolving histopathologic changes (3 hour, 12 hour, 1 day, 2day, 3day, 4day after reperfusion).

2.4 Examination of neuronal damage: NeuN immunohistochemistry

The sections in the hippocampal CA1 region were sequentially treated with 0.3% hydrogen peroxide in PBS for 30 min and 10% goat serum in 0.05 M PBS for 30 min. The sections were next incubated with diluted mouse anti-NeuN (diluted 1:1,000, Chemicon International, Temecula, CA) overnight at room temperature. Thereafter the tissues were exposed to biotinylated goat anti-mouse IgG and streptavidin peroxidase complex (Vector, Burlingame, CA). And they were visualized with 3,3’-diaminobenzidine in 0.1 M Tris-HCl buffer and
mounted on the gelatin-coated slides. After dehydration the sections were mounted in Canada Balsam (Kanto Chemical).

2.5 Examination of neuronal apoptosis: TUNEL staining
The sections in the hippocampal CA1 region were stained using terminal deoxyxynucleotidyl transferase dUTP-biotin nick-end-labeling (TUNEL) staining. The sections were washed in 0.1 M PBS (pH 7.4) for 30 min before being incubated in blocking solution (3% H2O2 in 0.01 M PBS) at room temperature for 20 min, and were then washed in PBS for 5 min and treated with permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) at 4°C for 2 min. Next, the sections were washed 3 times, and then incubated in TUNEL reaction mixture according to kit instructions (Roche Molecular Biochemicals, Mannheim, Germany). The TUNEL reaction mixture was prepared with a 1:2 dilution of the enzyme solution. The sections were washed 3 times with PBS (10 min per wash) before being incubated in converter-POD (Roche Molecular Biochemicals) at 37°C for 30 min and treated with DAB-substrate solution for 1.5-2 min. After washing the sections 3 times, the sections were counterstained with methyl green, dehydrated and coverslipped with Canada Balsam (Kanto Chemical).

2.6 Examination of neuronal damage: Fluoro-Jade B (F-J B) histofluorescence staining
According to the experiment of Candelario-Jalil et al (2003), the sections were first immersed in a solution containing 1% sodium hydroxide in 80% alcohol, and followed in 70% alcohol. They were then transferred to a solution of 0.06% potassium permanganate, and transferred to a 0.0004% F-J B (Histochem, Jefferson, AR) staining solution. After washing, the sections were placed on a slide warmer (approximately 50°C), and then examined using an epifluorescent microscope (Carl Zeiss, Göttingen, Germany) with blue (450-490 nm) excitation light and a barrier filter (Schmued and Hopkins, 2000).

2.7 Immunohistochemistry for 8-hydroxy-2’-deoxyguanosine (8-OHdG)
At designated times (30 min, 3 h, 6 h, 12 h, 24 h, 2 days, 3 days and 4 days) after the surgery, sham- and ischemia-operated animals (n = 7 at each time point) were used for this experiment. To obtain the exact data in this study, tissues of sham-operated and operated animals were processed under the same conditions. The sections were sequentially treated with 0.3% hydrogen peroxide in PBS for 30 min, 150 μM/ml RNase A for 1 h at 37°C, 50 mM sodium hydroxide in 40% ethanol for 10 min. The sections were incubated with mouse anti-8-OHdG antiserum (1:100) (Bail et al., 1996; Won et al., 1999, 2001) in PBS containing 0.3% Triton X-100 and 2% normal goat serum overnight at room temperature. After washing 3 times for 10 min with PBS, the sections were incubated sequentially, in goat anti-mouse IgG and Vectastain (Vector), diluted 1:200 in the same solution as the primary antiserum. Between incubations, the tissues were washed with PBS 3 times for 10 min each. The sections were visualized using 3,3’-diaminobenzidine tetrachloride (Sigma) in 0.1 M Tris-buffer and mounted on gelatin-coated slides.

2.8 Platelet endothelial cell adhesion molecule-1 (PECAM-1) staining
Immunohistochemistry for PECAM-1 (final mediator of neutrophil transendothelial migration) was conducted according to the method by Hwang et al (2005b). In brief, the sections were sequentially treated with 0.3% hydrogen peroxide (H2O2) in PBS and 10%
normal horse serum in 0.05 M PBS. The sections were next incubated with diluted mouse anti-PECAM-1 antibody (diluted 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) overnight. Thereafter, the tissues were exposed to biotinylated horse anti-mouse IgG and streptavidin-peroxidase complex (Vector). The sections were visualized with DAB in 0.1 M Tris-HCl buffer and mounted on the gelatin-coated slides.

2.9 Immunohistochemistry for glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba-1)

In order to examine the degree of reactive gliosis in the CA1 region in the CD- and FAD-treated groups after ischemia/reperfusion, we carried out immunohistochemical staining with rabbit anti-GFAP (diluted 1:1,000, Chemicon) for astrocytes and rabbit anti-Iba-1 (diluted 1:500, Wako, Osaka, Japan) for microglia according to the above mentioned-method (see the NeuN immunohistochemistry). The tissues were exposed to biotinylated goat anti-rabbit IgG (diluted 1:200; Vector) and streptavidin peroxidase complex (diluted 1:200; Vector). And they were visualized with DAB in 0.1 M Tris-HCl buffer and mounted on the gelatin-coated slides. After dehydration the sections were mounted in Canada Balsam (Kanto Chemical).

2.10 Quantification of data

All measurements were performed in order to ensure objectivity in blind conditions, by two observers for each experiment, carrying out the measures of control and experimental samples under the same conditions.

The number of survived pyramidal cells in the stratum pyramidale within the CA1 region was counted using an AxioM1 light microscope (Carl Zeiss) photomicroscope at a magnification of 400×. Histologic analysis was performed by a blinded observer and the average of the right and left survived cell numbers (neurons per 1 mm linear length) in a single section of the dorsal hippocampal CA1 region was calculated as reported by Kirino group (1986). Five sections of cresyl violet/NeuN and TUNEL/F-J B staining from each animal were used for counting.

Fifteen sections from a animal were randomly selected from the corresponding areas of the hippocampus in order to quantitatively analyze 8-OHdG, GFAP, Iba-1 and PECAM-1 immunoreactivity in the hippocampal CA1 region. The mid-point areas of the hippocampal CA1 region were measured on the monitor at a magnification of 25-50×. Images of all 8-OHdG, GFAP, Iba-1 and PECAM-1 immunoreactive structures taken from 3 layers (strata oriens, pyramidale and radiatum in the hippocampus proper, and molecular, granule cell and polymorphic layers in the dentate gyrus) were obtained through light microscope (Carl Zeiss, Germany). The staining intensity of all 8-OHdG, GFAP, Iba-1 and PECAM-1 immunoreactive structures was evaluated on the basis of a optical density (OD).

3. Results

3.1 Folate deficient change of body weight and serum concentration of homocysteine

Folate deficiency rendered the FAD-(folate deficient-diet) group susceptible to ischemia/reperfusion. After 3 months on the folate deficient-diets, serum levels of
homocysteine were determined and found to be 5- to 8-fold higher in gerbils subjected to FAD compared to CD-(control diet) group. The body weight gain during the first diet month was significantly lower in the FAD group than in the CD group, this was consistent throughout the 3 months of observation.

3.2 Neuronal damage
Cresyl violet and NeuN stainings show the positive pyramidal neurons on the first day. The cell densities decreased over the time after ischemia/reperfusion. Two days after ischemia/reperfusion, neurodegeneration were found in the neurons in the FAD-group (Figs. 1F, 1N), when no significant changes were seen in the CD-group (Figs. 1B, 1J). In FAD-group, CA1 pyramidal neurons showed cytoplasmic shrinkage and chromatic condensation. Starting from day three after ischemia/reperfusion, pyramidal neurons in FAD-group showed delayed neuronal death, which became morphologically similar to that of day four in CD-group (Figs. 1D, 1G, 1K and 1O). Delayed neuronal death in the CA1 region was identified using TUNEL or F-J B staining. CA1 pyramidal neurons in the CD- and FAD-groups 1 day after ischemia/reperfusion did not show TUNEL or F-J B staining (Figs. 2B, 2F, 2J, 2N). Two days after ischemia/reperfusion, pyramidal neurons in the FAD-group showed TUNEL or F-J B staining representing neurodegeneration (Figs. 2G, 2O). Four days after ischemia/reperfusion, pyramidal neurons in the CD-group showed TUNEL or F-J B staining (Figs. 2D, 2L), but TUNEL or F-J B stained pyramidal neurons decreased in FAD-group (Figs. 2H, 2P). These shows that folate deficiency enhances delayed neuronal death in the hippocampus after transient cerebral ischemia.

3.3 Change in 8-hydroxy-deoxyguanosine immunoreactivity
In this study, we found a significant difference in 8-hydroxy-deoxyguanosine immunoreactivity between the CD- and FAD-groups after ischemia/reperfusion (Figs. 3, 4). In both the sham-operated groups, very weak 8-hydroxy-deoxyguanosine immunoreactivity was detected in the CA1 region (Figs. 3A, 3E). The oxidative change in both groups began to increase at 30 min after ischemia/reperfusion, which the peak changes were noted at 12 hour after ischemia/reperfusion (Figs. 3C, 3G, Fig 4). At 12 hour after ischemia, 8-hydroxy-deoxyguanosine immunoreactivity in FAD-group was much higher than that in CD-group (Fig. 4). Thereafter, it decreased with time (Figs. 3D and 4). Four days after ischemic insult, 8-OHdG immunoreactivity in both groups was lower than that in the sham-operated groups (Fig. 4).

3.4 Change in PECAM-1 immunoreactivity
PECAM-1 immunoreactivity in microvessels in the hippocampal CA1 region changed after ischemia/reperfusion (Figs. 5, 6). In the CD- and FAD-fed-sham-operated groups, microvessels showed weak PECAM-1 immunoreactivity (Fig. 5A, 5B), and this immunoreactivity increased with time after ischemic insult in both of these groups (Figs. 5C-5H, Fig 6). PECAM-1 immunoreactivity in CA1 in both groups increased significantly 3 days after ischemia/reperfusion (Figs. 5G, 5H, Fig 6) and PECAM-1 immunoreactivity in FAD-group was much higher than that in CD-group (Fig. 6).
Fig. 1. Cresyl violet (CV) and NeuN staining of the CA1 region in sham-operated (A,E,I,M) and ischemia-operated groups 2 days (B,F,J,N), 3 days (C,G,K,O) and 4 days (D,H,L,P) after ischemia/reperfusion and feeding with a folic acid-deficient or control diet. Two days after ischemia/reperfusion, CV- or NeuN-positive pyramidal neurons in the folate-deficient diet-treated group show cytoplasmic shrinkage and chromatic condensation. Three days after ischemia/reperfusion, CV- or NeuN-positive pyramidal neurons in the folate-deficient diet-treated group show “delayed neuronal death” like that in the control diet-treated group 4 days after ischemia/reperfusion. SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum.
Fig. 2. TUNEL and Fluoro-Jade B (F-JB) staining of the CA1 region in the sham-operated (A,E,L,M) and ischemia-operated groups 1 days (B,F,J,N), 2 days (C,G,K,O), and 4 days (D,H,L,P) after ischemia/reperfusion and feeding with a folic acid-deficient or control diet. Two days after ischemia/reperfusion, TUNEL- or F-JB-positive pyramidal neurons are observed in stratum pyramidale (SP) of the folate-deficient diet-treated group. Four days after ischemia-reperfusion, TUNEL or F-JB reaction decreases in pyramidal neurons in the SP of the folate-deficient diet-treated group. SO, stratum oriens; SR, stratum radiatum.
Fig. 3. Immunohistochemistry for 8-hydroxy-deoxyguanosine in the CA1 region in the control diet- and folate deficient diet-sham (A,E) and ischemia-operated groups at 3 hr (B,F), 12 hr (C,G), and 2 days (D,H) after ischemia/reperfusion. At 12 hr after ischemic insult, 8-hydroxy-deoxyguanosine immunoreactivity in both groups is highest in CA1 (C,G), showing more dense immunoreactivity in folate-deficient diet- than in the control diet-group. Two days after ischemia/reperfusion, 8-hydroxy-deoxyguanosine immunoreactivity in folate-deficient diet-group is much lower than that in control diet-group (D,H). SP, stratum pyramidale; SO, stratum oriens; SR, stratum radiatum.
Fig. 4. Relative optical density (ROD) as percentage of 8-hydroxy-deoxyguanosine immunoreactivity in the CA1 region after transient ischemia (n= 5-7 per group; aP < 0.05 significantly different from the control diet- or folate-deficient diet-fed sham-operated group, bP < 0.05 significantly different from the control diet- or folate-deficient diet-treated preadjacent group, cP < 0.05 between the control diet- and the folate deficient diet-groups). Bars indicate means ± SEM.

Fig. 5. Immunohistochemistry for platelet endothelial cell adhesion molecule-1 (PECAM-1) in the CA1 region in sham-operated (A,E) and in ischemia-operated groups at 3 hr (B,F), 1 day (C,G), and 3 days (D,H) after ischemia/reperfusion in control diet- and folate-deficient diet-groups. In control diet-(A) and folate-deficient diet -sham-operated (E) groups, weak PECAM-1 immunoreactivity is detected in microvessels. Three days after ischemia /reperfusion, PECAM-1 immunoreactivity in both groups increased significantly (G,H); the immunoreactivity in folate deficient diet-group is higher than that in control diet-group. SP, stratum pyramidale; SO, stratum oriens; SR, stratum radiatum.
3.5 Reactive gliosis

Significant morphological changes were observed in glial cells in the CA1 region in the CD- and FAD-groups after ischemia/reperfusion. This change began 2 days after ischemia/reperfusion (Figs. 7).

Astrocytes. In the FAD-sham-operated group, weak GFAP immunoreactivity was detected in the CA1 region as in the CD-group (Fig. 7A, 7E). GFAP immunoreactive astrocytes had thin processes. Two days after ischemia/reperfusion, many astrocytes showed morphological changes in both groups (Fig. 7B, 7F), although at this time many more astrocytes in the FAD-treated group showed hypertrophied processes. Three days after ischemia/reperfusion, GFAP immunoreactive astrocytes in the FAD-treated group showed punctuated cytoplasm, whereas in the CD-group the cytoplasm of GFAP immunoreactive astrocytes was hypertrophied (Fig. 7C, 7G). Four days after ischemia/reperfusion, the processes of GFAP-immunoreactive astrocytes became hypertrophied, and the number and immunoreactivity in GFAP-immunoreactive astrocytes in the FAD-group were higher in the CD-group (Figs. 7D, 7H).

Microglia. Iba-1 immunoreactivity in the FAD-sham-operated group was similar to that in the CD-sham-operated group (Figs. 7I, 7M). Microglia in the CD-group were activated 2 days after ischemia/reperfusion, and many activated microglia in the FAD-group had aggregated to the stratum pyramidale, in which pyramidal neurons showed delayed neuronal death (Fig. 7J, 7N). Three days after ischemia/reperfusion, Iba-1 immunoreactive microglia in the FAD-group were concentrated in the stratum pyramidale of the CA1 region (Fig. 7O), whereas in the CD-group Iba-1 immunoreactive microglia were dispersed in CA1 (Fig. 7K). Four days after ischemia/reperfusion, microgliosis in the FAD-group was severer than in the CD-group (Figs. 7L, 7P).
Fig. 7. Immunohistochemistry for GFAP representing astrocytes and Iba-1 representing microglia in the CA1 region in sham-operated (A,E,I,M) and ischemia-operated groups 2 days (B,F,J,N), 3 days (C,G,K,O), and 4 days (D,H,L,P) after ischemia/reperfusion and feeding with folate-deficient diet or control diet. GFAP immunoreactivity-punctuated astrocytes in folate-deficient diet-group are detected 3 days after ischemia/reperfusion, whereas, in control diet-group, they are detected 4 days after ischemia/reperfusion. An increase of Iba-1-immunoreactive microglia is noted 3 days after ischemia/reperfusion in the stratum pyramidale of folate-deficient diet-group, whereas, in control diet-group, Iba-1-immunoreactive microglia is markedly increased 4 days after ischemia/reperfusion.
4. Discussion

Folate deficiency is a common condition, especially in geriatric population which is caused by environmental and genetic factor. The genetic variant of methylenetetrahydrofolate reductase is very common (10-15%). Moderate hyperhomocysteinemia (15-30 μmol/L) is very common condition which is linked to increased risk of atherothrombotic vascular disease (Yoo et al). Low dietary intake of folic acid is associated with increased homocysteine levels and an increased risk of heart disease and stroke (Giles et al., 1995; hankey GJ et al, 2001). Homocysteine has direct effects on the endothelium (Wall et al,1980; Kamath et al., 2006; Lominadze et al., 2006) and astrocytes (Kranich et al., 1998), which are mediate signaling between endothelium and neurons (Nedergaard et al., 2003). In addition, the treatment of folic acid with vitamin B12 and B6 improves the blood-brain barrier function in human (Lehmann et al., 2003). Among the hypoxic brain damage, most sensitive are the pyramidal neurons in the CA1 region of the hippocampus. In experimental animal, transient forebrain ischemia, which temporarily deprives the brain of glucose as well as oxygen, results in the insidious delayed degeneration of specific vulnerable neurons within the CA1 region of the hippocampus (Kirino, 1982; Pulsinelli et al., 1982). In FAD-group, cresyl violet or NeuN positive neurons began to decrease day 2 after ischemia/reperfusion, while in CD-group, cresyl violet or NeuN positive neurons began to decrease day 3 after ischemia/reperfusion. Delayed neuronal death of CA1 pyramidal neurons in the CD-groups occurred day 4 after ischemia/reperfusion, whereas in the FAD-group, delayed neuronal death in CA1 pyramidal neurons occurred day 3 after ischemia/reperfusion. In addition, CA1 pyramidal neurons in the FAD-group showed TUNEL or F-J B staining representing neurodegeneration day 2 after ischemia/reperfusion. This is the first report that neuronal damage in the ischemic CA1 region is accelerated by folate deficiency.

4.1 Excitotoxicity of homocysteine

Homocysteine is easily carried into neuronal cells via a specific membrane transporter, leading to high intracellular homocysteine concentrations (Grieve et al., 1992). It has been shown that homocysteine and its metabolic derivatives activate both group I metabotropic glutamate receptors (mGluR) (Dalton et al, 1997) and NMDA receptors (Pullan et al., 1987), suggesting the role of homocysteine-induced excitotoxicity. Homocysteine can play as an endogenous glutamate receptor agonist (Lipton et al, 1997; Do et al, 1986; Ito et al, 1991) by activating on N-methyl-D-aspartate(NMDA) receptor subtype. The oxidative product of homocysteine, homocysteic acid, can functions as an excitatory neurotransmitter by activating NMDA receptor (Olney et al, 1987) The neurotoxicity of homocysteic acid in the brain can be partially abrogated by using a NMDA antagonist, suggesting a role for agonistic function (Olney et al, 1987; Kim et al, 1987).

Depending on glycine concentration, homocysteine showed dual response. In the condition of low glycine, homocysteine acts as a antagonist of the glycine site of the NMDA receptor, resulting in neuroprotective function. However, in the situation of high glycine levels after brain ischemia, homocysteine can bind and activate NMDA receptor, leading to excitotoxic damage (Lipton et al, 1997). These actions suggest that folate deficiency accompanied by hyperhomocysteinemia may contribute to the early brain damage after ischemia.

In addition, homocysteine has been reported to induce an extra-cellular signal regulated kinase in the hippocampus(Robert et al, 2005). Homocysteine also activates group I
metabotropic glutamate receptors (mGluR1), leading to activation of protein kinase C and increased intracellular IP3 formation, increasing the intracellular calcium ion, especially in endoplasmic reticulum (Dalton et al, 1997).

4.2 Homocysteine and apoptosis pathway
Homocysteine-induced ROS generation enhances the activation of NF-kB (Chern et al., 2001). NF-kB is one of the transcriptional factors that can be controlled by the cellular redox status. NF-kB plays a role in the control of oxidative stress-mediated apoptosis. In the oxidative conditions, neuronal cell death derives from excessive calcium influx and ROS leading to excitotoxicity. In a transient middle cerebral artery occlusion experiment, increased DNA binding was detected after reperfusion following 2 hour ischemia (Schneider et al., 1999), suggesting the activation of NF-kB. Increased transcriptional activity of NF-kB has been identified in mouse models of both permanent and transient cerebral ischemia using kB-dependent β-globin reporter gene assay (Schneider et al., 1999). NF-kB target genes include proinflammatory cytokines shown to be expressed in cerebral ischemia. TNF, IL-6, inducible nitric oxide synthase, intercellular adhesion molecule 1 (ICAM-1), and matrix metalloproteinase (MMP) 9 are major players in the post-ischemic inflammation of brain (Wang et al., 2007; Gilmore, 2008). IL-1 α and IL-1β are rapidly induced in cerebral ischemia (Allan et al., 2005).

4.3 Hyperhomocysteinemia and hypercoagulable state of blood
The mechanism by which hyperhomocysteinemia can cause the hypercoagulable state of blood and an increased risk of thrombosis has poorly established. There have been growing evidences from the various aspects. In vitro study of cultured cells showed a toxic effect of homocysteine on endothelial cell viability (Wall, 1980). Cultured endothelial cells under high concentration of homocysteine were not viable with copper that led to the oxidation of homocysteine, concomitant with hydrogen peroxide generation (Starkebaum and Harlan, 1986). Homocysteine inhibited the synthesis of prostacyclin, a potent inhibitor of platelets in cultured cells (Wang, 1993). In vitro studies have shown that high concentration of homocysteine promote blood clotting cascade. Homocysteine activated factor V on cultured endothelial cells (Rodgers and Kane, 1986) and inhibited protein C activation in cultured endothelial cells (Rodgers, 1990). At concentrations greater than 5mmol/L, homocysteine inhibited thrombomodulin surface expression (thrombomodulin promote activation of the anticoagulant protein C and inhibit procoagulant activity of thrombin) (Lentz , 1991). Homocysteine blocked tissue-type plasminogen activator in endothelial cells (Hajjar, 1993). Homocysteine increased platelet adhesion (Blann, 1992), and induced tissue factor (Fryer, 1993), and suppressed anticoagulant, heparan sulfate expression (Nishinaga, 1993). It has been documented that homocysteine level as low as 8 micromol/L increased affinity of lipoprotein(a) for plasmin modified fibrin surfaces, inhibiting plasminogen activation (Harpel, 1992). In vivo studies showed an abnormally increased biosynthesis of thromboxane A2 in patients with CBS deficiency (Di Minno, 1993), and endothelial dysfunction (Lentz, 1996). It have been reported that impaired regulation of endothelium-derived relaxing factor & nitrogen oxides (Stamler, 1993) and oxidation of low-density lipoprotein in vitro (Pathasarathy, 1987). Folate deficiency may contribute the development of atherothrombogenic condition. In the rat model, dietary folate deficiency, a major cause
of hyperhomocysteinemia, was associated with 20-fold enhanced macrophage-derived tissue factor activity and increased ADP- and thrombin-induced platelet aggregation (Durand et al, 1996). In vitro endothelial cell study, cell treated with homocysteine showed a significant decrease in glutathione peroxidase transcription and activity, suggesting the impairment of endothelial ability to detoxify oxidative stress and leading to attenuation of bioavailable nitric oxide, a potent anti-thrombotic factor (Upchurch, 1997).

Recent oligo-array technology data validated by real time reverse transcriptase-polymerase chain reaction showed the changed gene expression in animal fed folate deficient diet, suffering from hyperhomocystinemia. Folate deficiency upregulate integrin beta-3, Rap1b, glycoprotein V, platelet-endothelial cell adhesion molecule-1(PECAM-1) and von Willebrand factor, leading to platelet activation and aggregation. In addition, upregulation of coagulation factor XIIIa, plasminogen activator inhibitor-1, and down regulation of tissue-type plasminogen activator were observed (Ebbesen LS et al, 2006).

4.4 Oxidative stress and neurotoxicity in hyperhomocysteinemia and folate deficiency

The highly reactive sulphydryl group in the homocysteine is readily oxidized to generate reactive oxygen species (Starkebaum and Harlan, 1986), suggesting that homocysteine can cause cell injury through a mechanism involving oxidative damage. The oxidative stress has been noted that hyperhomocysteinemia and folate deficiency induces or potentiates the toxic effects on the neuronal cells in vivo or in vitro. In early study, Wall et al.(1980) showed homocysteine oxidation is related to hydrogen peroxide generation. In human neuroblastoma cells cultured in folate-deprived media, oxidative stress played a role for homocysteine toxicity in neuronal cells (Ho et al, 2003). The cytotoxicity of homocysteine was compromised by antioxidants including N-acetyl cysteine, vitamin E or C (Reis et al, 2002; Wyse et al, 2002). Antioxidants vitamin including vitamin E or C prevented memory dysfunction induced by homocysteine administration in the rats (Reis et al, 2002) and the reduction of Na-K ATPase activity caused by hyperhomocysteinemia in rats(Wyse et al, 2002). Folate deficiency decreased the proliferating cells in the dentate gyrus of adult mice hippocampus (Kruman et al, 2005). Folate deprivation led to pronounced hyperhomocysteinemia and reactive oxygen species. Folate deficient condition increased amyloid-beta-induced apoptosis, while high level of folate supplementation abrogated the reactive oxygen species generation by amyloid-beta(Ho et al, 2003). Folate deprivation in neuroblastoma cells showed an increased immunoreactivity of phospho-tau (Ho et al, 2003). In apolipoprotein E-deficient mice, iron challenge increased oxidative stress in folate deprived animals, but not in vitamin E. Oxidative damage can be mitigated by folate supplementation by reducing intracellular superoxide generation or scavenging hydrogen peroxide. (Shea and Rogers, 2002). In primary culture of rat cerebellar granular cells, homocysteine neurotoxicity was partially prevented by NMDA receptor antagonist. Homocysteine-induced neuronal death was effectively blocked by the combination of catalase and superoxide dismutase or catalase alone. These findings support that the homocysteine-induced neurotoxicity is based on the oxidative stress and excitotoxicity(Kim and Pae, 1996).

A number of evidence supports the roles of DNA damage and apoptosis in the pathogenesis of several neurodegenerative disorders, including cerebral ischemia (Liu et al., 1996; Won et al., 1999, 2001; Bazan, 2005). In the present study, 8-hydroxy-deoxyguanosine immunoreactivity in the CA1 region in FAD-group increased in advance of that in CD-group, and its peak level was noted at 12 hour after ischemia/reperfusion, which was more
pronounced in FAD-group. This result indicates that CA1 neurons in folate deficient condition are more vulnerable to ischemic DNA damage.

Endres et al. (2005) reported that cerebral lesion volumes after ischemia and 72-hour reperfusion were significantly increased by 2.1-fold in folic acid-deficient 129/SV wild-type mice versus controls on a normal diet, and this could not be explained by obvious differences in physiological parameters. They also reported that abasic sites, a marker of oxidative DNA damage, are significantly increased in DNA from the ischemic brains of folate-deficient 129/SV wild-type mice at early time points after MCA occlusion than control mice (Endres et al., 2005). These are supported by those of previous studies which found that folate deficiency in humans induces extensive chromosome damage, fragile site expression, micronucleus formation, and increased uracil levels in bone marrow cell DNA (Blount et al., 1997; Crott et al., 2001). The misincorporation of uracil appears to be a key event in the neurotoxicity associated with folate deficiency, because the pretreatment of culture medium with thymidine and hypoxanthine (precursors of purines) reduces neuronal cell death induced by methyl donor deficiency (Blount et al., 1997). Folate deficiency could cause the misincorporation of uracil into the DNA of proliferating cells caused by the impairment of deoxynucleoside triphosphate pools (Pogribny et al., 1997; Mol et al., 1999). In addition, homocysteine is rapidly taken up by neurons via a specific membrane transporter. Increased levels of homocysteine in cell nuclei may induce DNA strand breaks by disturbing the DNA methylation cycle (Blount et al., 1997) or may promote DNA damage accumulation in neurons by impairing DNA repair (Kruman et al., 2002).

4.5 Folate deficiency and platelet endothelial cell adhesion molecule-1

Adhesion and trans-endothelial migration of leucocytes play a significant roles in the pathophysiologic events in brain inflammation after stroke. Platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) is a 130-kDa protein member of the immunoglobulin gene superfamily, which is expressed on the surface of platelets, monocytes, neutrophils, selected T cell subsets and on endothelial cell intercellular junctions (Newman, 1997). Expression levels of PECAM-1 differ in the type of organ tissues. It is highly expressed in kidney, lung, and trachea, while its level is at lower in brain, heart and liver. But, fibroblasts, epithelial cells, muscle, nonvascular cells or red blood cells do not express it. (Newman, 1997; Wang, 2003).

Muller et al. (1993) showed for the first time that monocytes or neutrophils treated with the specific antibodies for PECAM-1 blocked transmigration across the endothelial monolayer in vitro assay. Blocking endothelial cell junctional PECAM-1 also inhibited leukocyte transmigration, indicating that PECAM-1 molecules on both the endothelial cell as well as the leukocyte side contributed to the transmigration process. Most of PECAM in endothelium is distributed in the intercellular junctions, and 15% is on the exposed apical surface. Qing et al(2001) found that anti-PECAM-1 antibody or PECAM-Ig chimeric molecule injection blocked the T cell trafficking into the CNS in TCR transgenic mice during inflammation. Rosenblum et al.(1994) demonstrated that anti-CD31 mAb injection before the damage of endothelium in pial arteriole of mouse doubled the platelet aggregation time. Vaporciyan et al. (1993) also showed that antibody to human PECAM-1 could block in vivo accumulation of rat neutrophils into the peritoneal cavity and the alveolar compartment of the lung. These results suggest that PECAM-1 plays a key role in the transendothelial migration of leukocytes in the process of inflammation. Gumina et al.(1996) showed that
antibodies to PECAM-1 reduce myocardial infarct size in both rat. and Murohara et al(1996) showed blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats.

Brain ischaemia eventually enhances local inflammatory reaction. Accumulated leucocytes adhere to endothelium, probably leading to the microvasculature occlusion (Schmid-Schonbein, 1987; del Zoppo et al, 1991). Hwang et al. (2005b) demonstrated that transient ischaemia in gerbils results in a significant increase of PECAM-1 immunoreactivity in the hippocampus. PECAM-1 expression was particularly prominent in the vulnerable neurons of the hippocampal CA1 region. PECAM-1 immunoreactivity was significantly increased by 4 days after ischaemia. In addition, serum sPECAM-1 levels in ischemic group were higher than those of sham group. Zaremba and Losy (2002). reported that sPECAM-1 increases significantly in serum and in CSF in patients within 24 h after ischaemic stroke, compared with control group. In addition, serum and CSF sPECAM-1 levels within 24 h after ischaemic stroke correlated to volume of early brain CT hypodense areas, indicating the cerebral hypoperfusion. This suggests that PECAM-1 may be involved in inflammatory response mediated extent of early ischaemic brain damage. Also, sPECAM-1 levels within 24 h and at second week after ischaemic stroke correlated positively with neurological stroke severity, and with the degree of functional disability within 24 h of stroke and at second week after the incident. Therefore, initial sPECAM-1 might be of predictive value for the short-term outcome of stroke ( Zaremba and Losy, 2002b).

O’Brien et al(2003) demonstrated that PECAM-1 mediates neutrophil migration through IL-1 beta stimulated endothelial cells. It has shown that hyperhomocysteinemia at moderate level activates human monocyte and induces cytokine expression including tumor necrosis alpha, IL-1 beta, IL-6, IL-8, and IL-12 (Su et al, 2005). In this experiment, PECAM-1 immunoreactivity in the CA1 region was higher in folate deficient group than in the controls. This result suggests that folate deficiency and elevated homocysteine can enhance inflammatory response in post ischemic condition through NF-kB activation. Increased gliosis in folate deficient group may be due to elevations of PECAM-1 immunoreactivity and of its protein level in vessels, inducing the transmigration of lymphocytes and neutrophils (Michiels et al., 1998; Dangerfield et al., 2002; Hwang et al., 2005b).

In summary, folate deficiency was found to induce early and significant neuronal death and gliosis in CA1 with concomitant oxidative DNA damage. These findings suggest that folate deficiency accelerate the pathological neuronal loss and inflammation that are activated after the onset of transient cerebral mild ischemia.

5. Acknowledgements

The author wish to thank Hwang IK, Yoo KY, Suh HW, Kim YS, Kwon DY, Kwon YG, and Won MH for excellent technical work. This work was supported by BioFoods Project in Korea Biotechnology Research Plan under the Ministry of Science and Technology of the Korea Government; Contract grant number: M10510120004-05N1012-00411; MRC program of MOST/KOSEF; R13-2005-022-01002-0; Samsung Biomedical Research Institute; CA5-220-1.

6. References

Folate Deficiency Enhances Delayed Neuronal Death in the Hippocampus After Transient Cerebral Ischemia


Harpel PC, Chang VT, Borth W. (1992). Homocysteine and other sulphhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulphhydryl compounds metabolism. Proc Natl Acad Sci USA 89:10193


Hwang IK, Yoo KY, Li H, Lee BH, Suh HW, Kwon YG, Won MH. (2007). Aquaporin 9 changes in pyramidal cells before and is expressed in astrocytes after delayed


Pathasarathy S. (1987). Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetylated LDL receptor. Biochim Biophys Acta 917:337


Yoo JH, Park SC. (2000). Low plasma folate in combination with the 677 C to T methylenetetrahydrofolate reductase polymorphism is associated with increased risk of coronary artery disease in Koreans. Thromb Res 97: 77-84.


This book reports innovations in the preclinical study of stroke, including - novel tools and findings in animal models of stroke, - novel biochemical mechanisms through which ischemic damage may be both generated and limited, - novel pathways to neuroprotection. Although hypothermia has been so far the sole "neuroprotection" treatment that has survived the translation from preclinical to clinical studies, progress in both preclinical studies and in the design of clinical trials will hopefully provide more and better treatments for ischemic stroke. This book aims at providing the preclinical scientist with innovative knowledge and tools to investigate novel mechanisms of, and treatments for, ischemic brain damage.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: